keyword
https://read.qxmd.com/read/38446044/noninvasive-molecular-subtyping-of-pediatric-low-grade-glioma-with-self-supervised-transfer-learning
#1
JOURNAL ARTICLE
Divyanshu Tak, Zezhong Ye, Anna Zapaischykova, Yining Zha, Aidan Boyd, Sridhar Vajapeyam, Rishi Chopra, Hasaan Hayat, Sanjay Prabhu, Kevin X Liu, Hesham Elhalawani, Ali Nabavizadeh, Ariana Familiar, Adam Resnick, Sabine Mueller, Hugo J W L Aerts, Pratiti Bandopadhayay, Keith Ligon, Daphne Haas-Kogan, Tina Poussaint, Benjamin H Kann
"Just Accepted" papers have undergone full peer review and have been accepted for publication in Radiology: Artificial Intelligence . This article will undergo copyediting, layout, and proof review before it is published in its final version. Please note that during production of the final copyedited article, errors may be discovered which could affect the content. Purpose To develop and externally test a scan-to-prediction deep-learning pipeline for noninvasive, MRI-based BRAF mutational status classification for pediatric low-grade glioma (pLGG)...
March 6, 2024: Radiology. Artificial intelligence
https://read.qxmd.com/read/38313265/aurora-kinase-a-inhibition-enhances-dna-damage-and-tumor-cell-death-with-131i-mibg-therapy-in-high-risk-neuroblastoma
#2
Prerna Kumar, Jessica Koach, Erin Nekritz, Sucheta Mukherjee, Benjamin S Braun, Steven G DuBois, Nicole Nasholm, Daphne Haas-Kogan, Katherine K Matthay, William A Weiss, Clay Gustafson, Youngho Seo
Background Neuroblastoma is the most common extra-cranial pediatric solid tumor. 131 I-metaiodobenzylguanidine (MIBG) is a targeted radiopharmaceutical highly specific for neuroblastoma tumors, providing potent radiotherapy to widely metastatic disease. Aurora kinase A (AURKA) plays a role in mitosis and stabilization of the MYCN protein in neuroblastoma. Here we explore whether AURKA inhibition potentiates a response to MIBG therapy. Results Using an in vivo model of high-risk neuroblastoma, we demonstrated a marked combinatorial effect of 131 I-MIBG and alisertib on tumor growth...
January 18, 2024: Research Square
https://read.qxmd.com/read/38221978/comparison-of-volumetric-and-2d-based-response-methods-in-the-pnoc-001-pediatric-low-grade-glioma-clinical-trial
#3
JOURNAL ARTICLE
Marc von Reppert, Divya Ramakrishnan, Sarah C Brüningk, Fatima Memon, Sandra Abi Fadel, Nazanin Maleki, Ryan Bahar, Arman E Avesta, Leon Jekel, Matthew Sala, Jan Lost, Niklas Tillmanns, Manpreet Kaur, Sanjay Aneja, Anahita Fathi Kazerooni, Ali Nabavizadeh, MingDe Lin, Karl-Titus Hoffmann, Khaled Bousabarah, Kristin R Swanson, Daphne Haas-Kogan, Sabine Mueller, Mariam S Aboian
BACKGROUND: Although response in pediatric low-grade glioma (pLGG) includes volumetric assessment, more simplified 2D-based methods are often used in clinical trials. The study's purpose was to compare volumetric to 2D methods. METHODS: An expert neuroradiologist performed solid and whole tumor (including cyst and edema) volumetric measurements on MR images using a PACS-based manual segmentation tool in 43 pLGG participants (213 total follow-up images) from the Pacific Pediatric Neuro-Oncology Consortium (PNOC-001) trial...
2024: Neuro-oncology advances
https://read.qxmd.com/read/38046107/re-irradiation-of-recurrent-idh-wildtype-glioblastoma-in-the-bevacizumab-and-immunotherapy-era-target-delineation-outcomes-and-patterns-of-recurrence
#4
JOURNAL ARTICLE
Sebastian M Christ, Gilbert Youssef, Shyam K Tanguturi, Daniel Cagney, Diana Shi, J Ricardo McFaline-Figueroa, Ugonma Chukwueke, Eudocia Q Lee, Caroline Hertler, Nicolaus Andratschke, Michael Weller, David A Reardon, Daphne Haas-Kogan, Matthias Guckenberger, Patrick Y Wen, Rifaquat Rahman
INTRODUCTION AND BACKGROUND: While recurrent glioblastoma patients are often treated with re-irradiation, there is limited data on the use of re-irradiation in the setting of bevacizumab (BEV), temozolomide (TMZ) re-challenge, or immune checkpoint inhibition (ICI). We describe target delineation in patients with prior anti-angiogenic therapy, assess safety and efficacy of re-irradiation, and evaluate patterns of recurrence. MATERIALS AND METHODS: Patients with a histologically confirmed diagnosis of glioblastoma treated at a single institution between 2013 and 2021 with re-irradiation were included...
January 2024: Clinical and Translational Radiation Oncology
https://read.qxmd.com/read/38020972/genetic-architecture-of-the-acute-and-persistent-immune-cell-response-after-radiation-exposure
#5
JOURNAL ARTICLE
Li He, Chenhan Zhong, Hang Chang, Jamie L Inman, Susan E Celniker, Myrsini Ioakeim-Ioannidou, Kevin X Liu, Daphne Haas-Kogan, Shannon M MacDonald, David W Threadgill, Scott C Kogan, Jian-Hua Mao, Antoine M Snijders
Hematologic toxicity is a common side effect of multimodal cancer therapy. Nearly all animal studies investigating the causes of radiotherapy-induced hematologic toxicity use inbred strains with limited genetic diversity and do not reflect the diverse responses observed in humans. We used the population-based Collaborative Cross (CC) mouse resource to investigate the genetic architecture of the acute and persistent immune response after radiation exposure by measuring 22 immune parameters in 1,720 CC mice representing 35 strains...
November 8, 2023: Cell Genom
https://read.qxmd.com/read/37978951/everolimus-for-children-with-recurrent-or-progressive-low-grade-glioma-results-from-the-phase-ii-pnoc001-trial
#6
JOURNAL ARTICLE
Daphne A Haas-Kogan, Mariam S Aboian, Jane E Minturn, Sarah E S Leary, Mohamed S Abdelbaki, Stewart Goldman, Jennifer D Elster, Adam Kraya, Matthew R Lueder, Divya Ramakrishnan, Marc von Reppert, Kevin X Liu, Jo Lynne Rokita, Adam C Resnick, David A Solomon, Joanna J Phillips, Michael Prados, Annette M Molinaro, Sebastian M Waszak, Sabine Mueller
PURPOSE: The PNOC001 phase II single-arm trial sought to estimate progression-free survival (PFS) associated with everolimus therapy for progressive/recurrent pediatric low-grade glioma (pLGG) on the basis of phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway activation as measured by phosphorylated-ribosomal protein S6 and to identify prognostic and predictive biomarkers. PATIENTS AND METHODS: Patients, age 3-21 years, with progressive/recurrent pLGG received everolimus orally, 5 mg/m2 once daily...
February 1, 2024: Journal of Clinical Oncology
https://read.qxmd.com/read/37945573/automated-temporalis-muscle-quantification-and-growth-charts-for-children-through-adulthood
#7
JOURNAL ARTICLE
Anna Zapaishchykova, Kevin X Liu, Anurag Saraf, Zezhong Ye, Paul J Catalano, Viviana Benitez, Yashwanth Ravipati, Arnav Jain, Julia Huang, Hasaan Hayat, Jirapat Likitlersuang, Sridhar Vajapeyam, Rishi B Chopra, Ariana M Familiar, Ali Nabavidazeh, Raymond H Mak, Adam C Resnick, Sabine Mueller, Tabitha M Cooney, Daphne A Haas-Kogan, Tina Y Poussaint, Hugo J W L Aerts, Benjamin H Kann
Lean muscle mass (LMM) is an important aspect of human health. Temporalis muscle thickness is a promising LMM marker but has had limited utility due to its unknown normal growth trajectory and reference ranges and lack of standardized measurement. Here, we develop an automated deep learning pipeline to accurately measure temporalis muscle thickness (iTMT) from routine brain magnetic resonance imaging (MRI). We apply iTMT to 23,876 MRIs of healthy subjects, ages 4 through 35, and generate sex-specific iTMT normal growth charts with percentiles...
November 9, 2023: Nature Communications
https://read.qxmd.com/read/37802460/popular-contraception-videos-on-tiktok-an-assessment-of-content-topics
#8
JOURNAL ARTICLE
Rachel E Stoddard, Andrea Pelletier, Emily N Sundquist, Maetal E Haas-Kogan, Bina Kassamali, Melody Huang, Natasha R Johnson, Deborah Bartz
OBJECTIVE: To explore the contraception content topics on the highly popular social media platform TikTok to understand this influential information source patients may bring into birth control counseling visits. STUDY DESIGN: Utilizing a snapshot method, we collected the 100 most popular TikTok English-language videos for each of eight contraception-specific search terms. We abstracted video content topics addressed and creator attributes. Two independent abstractors coded each video with high agreement, with a third coder adjudicating discrepancies...
October 4, 2023: Contraception
https://read.qxmd.com/read/37784672/a-genomic-score-to-predict-local-control-among-patients-with-brain-metastases-managed-with-radiation
#9
JOURNAL ARTICLE
N Lamba, D N Cagney, P J Catalano, D Kim, H Elhalawani, D A Haas-Kogan, P Y Wen, N Wagle, A A Aizer
PURPOSE/OBJECTIVE(S): Clinical predictors of local recurrence following radiation among patients with brain metastases (BrM) provide limited explanatory power. As a result, radiation doses and fractionation schemes are relatively homogeneous and prescribed with a "one-size-fits-all" approach. We hypothesized that tumor-specific genomic alterations may underlie radiation sensitivity among patients with BrM and sought to develop a DNA-based signature of radiation-based efficacy in this patient population, utilizing genes that are readily testable in modern-day assays, to identify subpopulations at greater vs...
October 1, 2023: International Journal of Radiation Oncology, Biology, Physics
https://read.qxmd.com/read/37784569/genomic-predictors-of-leptomeningeal-disease-development-among-patients-with-brain-metastases
#10
JOURNAL ARTICLE
N Lamba, D N Cagney, P J Catalano, H Elhalawani, D A Haas-Kogan, P Y Wen, N Wagle, A A Aizer
PURPOSE/OBJECTIVE(S): Leptomeningeal disease (LMD) is associated with significant neurologic symptomatology, functional decline, and generally, a very poor prognosis. Clinical characteristics of patients with parenchymal brain metastases have limited potential in predicting who will subsequently develop LMD. We hypothesized that genomic alterations may predict which patients with intracranial disease are at highest risk for developing LMD and sought to identify DNA-based genomic alterations among a targeted panel of cancer-related genes that may increase a patient's risk for LMD...
October 1, 2023: International Journal of Radiation Oncology, Biology, Physics
https://read.qxmd.com/read/37746299/clinical-outcomes-of-radiation-therapy-for-transgender-and-gender-expansive-people-with-cancer
#11
JOURNAL ARTICLE
Arian Mansur, Abigail M Kempf, Danielle S Bitterman, Chirayu G Patel, M Aiven Dyer, Daphne A Haas-Kogan, Kevin X Liu, Alicia C Smart
INTRODUCTION: Approximately 1.6 million people in the US identify as transgender, many of whom undergo gender-affirming medical or surgical therapies. While transgender individuals are diagnosed with cancer at similar rates as those who are cisgender, the impacts of radiation therapy on outcomes of gender-affirming care in transgender, nonbinary, and gender-expansive people with cancer are understudied. We report on the experiences and outcomes of transgender and gender-expansive patients receiving radiation therapy for cancer treatment...
2023: Frontiers in Oncology
https://read.qxmd.com/read/37722087/inaugural-results-of-the-individualized-screening-trial-of-innovative-glioblastoma-therapy-a-phase-ii-platform-trial-for-newly-diagnosed-glioblastoma-using-bayesian-adaptive-randomization
#12
JOURNAL ARTICLE
Rifaquat Rahman, Lorenzo Trippa, Eudocia Q Lee, Isabel Arrillaga-Romany, Geoffrey Fell, Mehdi Touat, Christine McCluskey, Jennifer Wiley, Sarah Gaffey, Jan Drappatz, Mary R Welch, Evanthia Galanis, Manmeet S Ahluwalia, Howard Colman, L Burt Nabors, Jaroslaw Hepel, Heinrich Elinzano, David Schiff, Ugonma N Chukwueke, Rameen Beroukhim, Lakshmi Nayak, J Ricardo McFaline-Figueroa, Tracy T Batchelor, Mikael L Rinne, Thomas J Kaley, Christine Lu-Emerson, Ingo K Mellinghoff, Wenya Linda Bi, Omar Arnaout, Pier Paolo Peruzzi, Daphne Haas-Kogan, Shyam Tanguturi, Daniel Cagney, Ayal Aizer, Lisa Doherty, Maria Lavallee, Brittany Fisher-Longden, Shanna Dowling, Jack Geduldig, Fiona Watkinson, William Pisano, Seth Malinowski, Shakti Ramkissoon, Sandro Santagata, David M Meredith, E Antonio Chiocca, David A Reardon, Brian M Alexander, Keith L Ligon, Patrick Y Wen
PURPOSE: The Individualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT) is a phase II platform trial that uses response adaptive randomization and genomic profiling to efficiently identify novel therapies for phase III testing. Three initial experimental arms (abemaciclib [a cyclin-dependent kinase [CDK]4/6 inhibitor], neratinib [an epidermal growth factor receptor [EGFR]/human epidermal growth factor receptor 2 inhibitor], and CC-115 [a deoxyribonucleic acid-dependent protein kinase/mammalian target of rapamycin inhibitor]) were simultaneously evaluated against a common control arm...
September 18, 2023: Journal of Clinical Oncology
https://read.qxmd.com/read/37703864/radiotherapy-for-primary-pediatric-central-nervous-system-malignancies-current-treatment-paradigms-and-future-directions
#13
REVIEW
Kevin X Liu, Daphne A Haas-Kogan, Hesham Elhalawani
BACKGROUND: Central nervous system tumors are the most common solid tumors in childhood. Treatment paradigms for pediatric central nervous system malignancies depend on elements including tumor histology, age of patient, and stage of disease. Radiotherapy is an important modality of treatment for many pediatric central nervous system malignancies. SUMMARY: While radiation contributes to excellent overall survival rates for many patients, radiation also carries significant risks of long-term side effects including neurocognitive decline, hearing loss, growth impairment, neuroendocrine dysfunction, strokes, and secondary malignancies...
September 13, 2023: Pediatric Neurosurgery
https://read.qxmd.com/read/37609311/noninvasive-molecular-subtyping-of-pediatric-low-grade-glioma-with-self-supervised-transfer-learning
#14
Divyanshu Tak, Zezhong Ye, Anna Zapaischykova, Aidan Boyd, Sridhar Vajapeyam, Rishi Chopra, Yining Zha, Hasaan Hayat, Sanjay Prabhu, Kevin X Liu, Hesham Elhalawani, Ali Nabavidazeh, Ariana Familiar, Adam Resnick, Sabine Mueller, Hugo J W L Aerts, Pratiti Bandopadhayay, Keith Ligon, Daphne Haas-Kogan, Tina Poussaint, Benjamin H Kann
PURPOSE: To develop and externally validate a scan-to-prediction deep-learning pipeline for noninvasive, MRI-based BRAF mutational status classification for pLGG. MATERIALS AND METHODS: We conducted a retrospective study of two pLGG datasets with linked genomic and diagnostic T2-weighted MRI of patients: Boston Children's Hospital (development dataset, N=214), and Child Brain Tumor Network (CBTN) (external validation, N=112). We developed a deep learning pipeline to classify BRAF mutational status (V600E vs...
August 8, 2023: medRxiv
https://read.qxmd.com/read/37534382/children-s-oncology-group-s-2023-blueprint-for-research-central-nervous-system-tumors
#15
JOURNAL ARTICLE
Sarah E S Leary, Arzu Onar-Thomas, Jason Fangusaro, Nicholas G Gottardo, Kenneth Cohen, Amy Smith, Annie Huang, Daphne Haas-Kogan, Maryam Fouladi
Tumors of the central nervous system (CNS) are a leading cause of morbidity and mortality in the pediatric population. Molecular characterization in the last decade has redefined CNS tumor diagnoses and risk stratification; confirmed the unique biology of pediatric tumors as distinct entities from tumors that occur in adulthood; and led to the first novel targeted therapies receiving Food and Drug Administration (FDA) approval for children with CNS tumors. There remain significant challenges to overcome: children with unresectable low-grade glioma may require multiple prolonged courses of therapy affecting quality of life; children with high-grade glioma have a dismal long-term prognosis; children with medulloblastoma may suffer significant short- and long-term morbidity from multimodal cytotoxic therapy, and approaches to improve survival in ependymoma remain elusive...
September 2023: Pediatric Blood & Cancer
https://read.qxmd.com/read/37486145/children-s-oncology-group-s-2023-blueprint-for-research-radiation-oncology
#16
JOURNAL ARTICLE
John A Kalapurakal, Suzanne L Wolden, Daphne Haas-Kogan, Nadia N Laack, Chia-Ho Hua, Arnold C Paulino, Christine E Hill-Kayser, Bradford S Hoppe, Thomas J Fitzgerald
Radiation oncology is an integral part of the multidisciplinary team caring for children with cancer. The primary goal of our committee is to enable the delivery of the safest dose of radiation therapy (RT) with the maximal potential for cure, and to minimize toxicity in children by delivering lower doses to normal tissues using advanced technologies like intensity-modulated RT (IMRT) and proton therapy. We provide mentorship for y ators and are actively involved in educating the global radiation oncology community...
September 2023: Pediatric Blood & Cancer
https://read.qxmd.com/read/37437812/multi-institutional-characterization-of-outcomes-for-pediatric-and-young-adult-patients-with-high-risk-myxopapillary-ependymoma-after-radiotherapy
#17
JOURNAL ARTICLE
Kevin X Liu, Daniel J Indelicato, Arnold C Paulino, Wen S Looi, Paul J Catalano, Murali M Chintagumpala, Sara L Gallotto, Karen J Marcus, Daphne A Haas-Kogan, Nancy J Tarbell, Shannon M MacDonald, Anita Mahajan, Torunn I Yock
PURPOSE: Myxopapillary ependymoma (MPE) is a rare, typically slow-growing subtype of spinal ependymomas. There are no standard guidelines for radiotherapy and long-term outcomes after radiation, particularly patterns of relapse, for pediatric and young adult (YA) patients with MPE remain under-characterized. MATERIALS AND METHODS: This is an Institutional Review Board-approved multi-institutional retrospective cohort study of 60 pediatric and YA patients diagnosed with MPE and received radiotherapy between 2000-2020...
July 10, 2023: International Journal of Radiation Oncology, Biology, Physics
https://read.qxmd.com/read/37425854/expert-level-pediatric-brain-tumor-segmentation-in-a-limited-data-scenario-with-stepwise-transfer-learning
#18
Aidan Boyd, Zezhong Ye, Sanjay Prabhu, Michael C Tjong, Yining Zha, Anna Zapaischykova, Sridhar Vajapeyam, Hasaan Hayat, Rishi Chopra, Kevin X Liu, Ali Nabavidazeh, Adam Resnick, Sabine Mueller, Daphne Haas-Kogan, Hugo J W L Aerts, Tina Poussaint, Benjamin H Kann
PURPOSE: Artificial intelligence (AI)-automated tumor delineation for pediatric gliomas would enable real-time volumetric evaluation to support diagnosis, treatment response assessment, and clinical decision-making. Auto-segmentation algorithms for pediatric tumors are rare, due to limited data availability, and algorithms have yet to demonstrate clinical translation. METHODS: We leveraged two datasets from a national brain tumor consortium (n=184) and a pediatric cancer center (n=100) to develop, externally validate, and clinically benchmark deep learning neural networks for pediatric low-grade glioma (pLGG) segmentation using a novel in-domain, stepwise transfer learning approach...
June 30, 2023: medRxiv
https://read.qxmd.com/read/37301262/serum-mirna-based-signature-indicates-radiation-exposure-and-dose-in-humans-a-multicenter-diagnostic-biomarker-study
#19
JOURNAL ARTICLE
Zuzanna Nowicka, Bartłomiej Tomasik, David Kozono, Konrad Stawiski, Thomas Johnson, Daphne Haas-Kogan, Marek Ussowicz, Dipanjan Chowdhury, Wojciech Fendler
PURPOSE: Mouse and non-human primate models showed that serum miRNAs may be used to predict the biological impact of radiation doses. We hypothesized that these results can be translated to humans treated with total body irradiation (TBI), and that miRNAs may be used as clinically feasible biodosimeters. METHODS: To test this hypothesis, serial serum samples were obtained from 25 patients (pediatric and adults) who underwent allogeneic stem-cell transplantation and profiled for miRNA expression using next-generation sequencing...
June 8, 2023: Radiotherapy and Oncology
https://read.qxmd.com/read/37260393/a-genomic-score-to-predict-local-control-among-patients-with-brain-metastases-managed-with-radiation
#20
JOURNAL ARTICLE
Nayan Lamba, Daniel N Cagney, Paul J Catalano, Dewey Kim, Hesham Elhalawani, Daphne A Haas-Kogan, Patrick Y Wen, Nikhil Wagle, Ayal A Aizer
BACKGROUND: Clinical predictors of local recurrence following radiation among patients with brain metastases (BrM) provide limited explanatory power. We developed a DNA-based signature of radiotherapeutic efficacy among patients with BrM to better characterize recurrence risk. METHODS: We identified 570 patients with 1,487 BrM managed with whole-brain (WBRT) or stereotactic radiation therapy at Brigham and Women's Hospital/Dana-Farber Cancer Institute (2013-2020) for whom next-generation sequencing panel data (OncoPanel) were available...
June 1, 2023: Neuro-oncology
keyword
keyword
37288
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.